Today: 9 June 2026
Schroders PLC share price slips as Goldman lifts target but sticks to “sell” on tariff jitters
19 January 2026
2 mins read

Schroders PLC share price slips as Goldman lifts target but sticks to “sell” on tariff jitters

London, January 19, 2026, 13:35 GMT — Regular session

  • Shares in Schroders slipped roughly 1.7% to about 459p during London trading
  • Goldman Sachs raises Schroders target to 395p but maintains a “sell” rating
  • Investors digest tariff news as Schroders prepares to release results on Feb. 12

Schroders’ shares slipped 1.7% to 459.2 pence by 1335 GMT on Monday, as investors processed a Goldman Sachs price target hike that still placed the stock below its current level. Goldman lifted its target for the UK fund manager from 380 to 395 pence but maintained a “sell” rating, according to an analyst summary. London South East

The dip is significant since Schroders recently enjoyed a strong rally, and its shares often reflect broader market sentiment. Fund managers rake in fees based on assets under management—the client funds they handle—so any market jitters can swiftly hit their revenues and investor confidence.

London’s wider market took a hit early on. By 1038 GMT, the FTSE 100 had slipped 0.6%, rattled by U.S. President Donald Trump’s threat to impose tariffs on Britain and seven other European countries if the U.S. isn’t given the chance to buy Greenland, denting risk appetite.

Schroders’ shares fluctuated between 456.4 pence and 463.0 pence during the session, down from a previous close of 467.0 pence. The stock remains close to the upper edge of its 52-week range, which spans from 249.1 pence to 472.8 pence.

Schroders issued a trading update on January 15, projecting adjusted operating profit for 2025 to hit at least £745 million. Adjusted net operating income is expected to be no less than £2.58 billion, while adjusted operating expenses should remain largely unchanged. The firm also highlighted group assets under management around £825 billion, including joint ventures, and net new business near £11 billion. It reaffirmed its goal of £150 million in annualised net savings by the end of 2027. Schroders cautioned these numbers are unaudited and could shift. Full-year results are scheduled for February 12.

Following the update, Citi analyst Nicholas Herman highlighted the implied profit run-rate for the second half, noting it stands roughly 25% above the Visible Alpha consensus.

The January 15 statement triggered a nearly 10% surge in Schroders shares and sent peer Ashmore sharply upwards that same day, driven by investor interest in improving flow and fee trends across the sector. Analysts at Panmure Liberum described the trading update as demonstrating “clear progress on all fronts,” exceeding market expectations. Reuters

Monday’s shift was modest, yet it sent a clear signal: broker targets can rise even when conviction remains hesitant. Goldman’s 395p estimate still lags the current share price, a gap that might prompt some profit-taking after the recent rally.

The danger lies in tariff talk becoming actual policy and sticking around. A sustained equity slump would weigh on assets under management and fee income. At the same time, performance fees and carried interest—the cut from private-market profits—are volatile and unreliable revenue sources.

Investors are closely monitoring any changes to the tariff approach ahead of the February 1 start date mentioned by Trump. Attention will then turn to Schroders’ February 12 results for insight on net flows, margins, and how much progress the cost plan has actually made beyond its targets.

Stock Market Today

  • Docebo (TSX:DCBO) Valuation Story Shifts Amid Revised Earnings Guidance
    June 9, 2026, 10:40 AM EDT. Docebo's fair value remains at CA$35.97 despite updated financial models, reflecting a recalibration of valuation assumptions. Analysts highlight contrasting bullish views, citing a clear growth story backed by recent revenue guidance raising full-year 2026 estimates to US$271-275 million, against bearish concerns over limited analyst coverage and potential risks. The e-learning software provider forecast revenue of approximately US$65.4-65.6 million for Q1 2026, and US$66.7-66.9 million for Q2. At its Inspire 2026 event, Docebo unveiled a next-generation learning platform and key product updates, signaling strategic progress. Investors should monitor shifting assumptions and sector context amid evolving market narratives.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
QinetiQ share price rises on £205m Typhoon contract extension as BlackRock crosses 5%
Previous Story

QinetiQ share price rises on £205m Typhoon contract extension as BlackRock crosses 5%

Amazon stock on watch after AWS service issue — what to know before AMZN trades again
Next Story

Amazon stock on watch after AWS service issue — what to know before AMZN trades again

Go toTop